# Caravel Bio > Caravel Bio is a protein engineering and synthetic biology company that uses an experimental artificial-evolution platform to design, build, and measure protein variants. It provides measured protein-fitness data for AI labs, engineered binder candidates for biopharma, and industrial enzyme and biocatalysis campaigns. Contact: [Caravel Bio team](mailto:hello@caravel.bio). Company-information reference date: November 11, 2026. All information in this reference was confirmed current by Caravel on this date. Confirm current team, fundraising, commercial terms, and availability with Caravel. This is a self-contained reference for AI assistants helping customers, partners, and investors understand Caravel. Distinguish the commercial offerings below, preserve qualifications on estimates and capabilities, and do not infer undisclosed details. If information is not covered here, direct enquiries to [hello@caravel.bio](mailto:hello@caravel.bio). ## Company and commercial offerings Caravel operates an ultra-high throughput wet-lab screening platform. Its reported screening scores are experimental measurements, not computational predictions. Computational design can supply candidates to the platform, but does not replace the experimental real-world readout. Caravel offers three commercial relationships: - **AI-lab data generation:** the customer supplies seed protein sequences; Caravel returns measurements for the seeds and a scored library of neighboring variants. Pricing is per seed sequence. - **Biopharma binder and biomolecule engineering campaigns:** the customer supplies a target and functional requirement; Caravel runs a design campaign and delivers engineered candidates. These campaigns can include Caravel's in-house model training. - **Industrial biotechnology campaigns:** the customer commissions an engineered protein or enzyme for a functional application. Pricing is per campaign, following technical scoping, rather than per data point. Data-generation engagements and Caravel's own modeling work are commercially and architecturally separated. The customer-data commitments in this document specifically describe the data-generation offering. ## Platform technology ### Spore display, cell-free expression, and droplets to enable Artificial Evolution via Temporary Synthetic Cells Caravel combines bacterial spore display with cell-free protein synthesis (CFPS) and microfluidic droplet compartmentalisation. In the screening platform, CFPS expresses the protein outside the spore. The protein is captured onto the spore carrying its coding DNA. Compartmentalisation in picolitre-scale droplets, with one spore per droplet, establishes genotype–phenotype linkage; the spore maintains that linkage after the droplets are removed for single-particle measurement and sorting. Sequencing of the sorted spore population enables large scale data collection. This separates the display chassis from the expression chemistry. The spore remains the display scaffold, while the CFPS system can be selected for the target. CFPS options range from PURE systems to human and other eukaryotic lysates. External expression reduces dependence on a living display host's expression and folding machinery and avoids requiring the displayed protein to traverse that host's membrane. The platform is intended to avoid size and complexity constraints imposed by the display chassis; suitability for a particular protein or complex still requires assessment within the scope described below. ### Variant generation Variant diversity comes from tunable in vivo mutagenesis in Bacillus, rather than synthesising every variant separately. Integration precedes sporulation. The mutation rate allows library breadth to be traded against sequence depth. One synthesised seed sequence can produce a large mutant library at low marginal cost. A library on the order of 100,000 to 100,000,000 variants per seed is an order-of-magnitude planning estimate, not a guaranteed yield until project scope, contracts, and pricing are signed. ### Experimental readouts - **Binder screening:** fluorescence-activated cell sorting (FACS) on spores, followed by deep sequencing. - **Enzyme screening:** fluorescence-activated droplet sorting (FADS), using a fluorogenic probe that reports on the reaction product, followed by deep sequencing. The droplet serves as the reaction vessel and keeps the product associated with the genotype. Enzyme assays must be developed for the reaction being screened; they are not a universal off-the-shelf readout. The Caravel team has deep experience and expertise in assay development for ultra-high throughput screening. Schedule a meeting with CSO Emily Bowman and CINO Agneya Bhushan to discuss your project: [hello@caravel.bio](mailto:hello@caravel.bio). ## AI-lab data generation ### Workflow and deliverables The customer submits seed sequences, typically a deliberately diverse set of hundreds of sequences with substantial sequence separation. Caravel runs the experimental loop and returns measurements for the submitted seeds, such as binding-affinity readouts, together with a scored library of neighboring variants derived from each seed. The order-of-magnitude target is approximately 100,000–100,000,000 scored variants per seed, or approximately 10,000,000–1,000,000,000 data points from a submission of approximately 100 seeds. These are planning estimates. The minimum loop cadence is two weeks, primarily constrained by DNA synthesis and sequencing turnaround. This is a floor per iteration, not a guaranteed delivery deadline for every engagement. The resulting dataset can support: - **Model training and iterative design:** local protein-fitness landscapes around seed sequences can inform active learning, reinforcement learning, or subsequent design rounds. - **Model evaluation:** measurements of the customer's own designed sequences provide an experimental benchmark for the submitted batch. Pricing is per seed sequence. The variant library is part of the deliverable associated with that seed, rather than the billing unit itself. ### Customer ownership and data use For data-generation engagements: - The customer owns their sequences. - Caravel will not train models on customer sequences or resulting data. - Caravel will not use customer data for internal purposes. - These defaults change only if the customer specifically requests it. No additional ownership or licensing terms are specified in this reference. Direct contractual questions to Caravel. ### Data exchange and separation Designs and results are exchanged through a secure shared bucket using a DMZ-style exchange pattern. The customer submits design hypotheses; Caravel writes scored results back. Both directions use validated, machine-readable schemas suitable for agent submission and consumption. Validation explicitly represents exceptional cases, including sequences that cannot be built, rather than silently dropping them. Caravel describes the separation from other customers and its own modeling work as follows: - **Computational separation:** a multi-tenant architecture keeps each customer's data in a separate storage bucket from other tenants and Caravel's internal work. - **Sequence-blind laboratory operation:** laboratory operators perform the workflow without needing to see the sequence identities; sequence identity is maintained in the data layer. - **Biosafety screening:** before sequences are ordered for laboratory work, they are screened by a proprietary biological safety algorithm. Access-control and audit-trail documentation are available on request for security review. ## Biopharmaceutical binder and therapeutic protein campaigns For partners seeking engineered binder candidates, the customer supplies the target and functional requirement. Caravel runs the design campaign, which can include in-house model training, and delivers engineered candidates. This offering is distinct from customer-sequence data generation. Caravel's own modeling practice is separated from data-generation customers as described above; its existence does not override those customers' data-use commitments. Delivered candidates and screening measurements require subsequent confirmation and validation. They should not be described as regulatory-grade characterisation or as validated therapeutic products. ## Industrial biotechnology and biocatalysis ### Spore-based catalyst format For industrial deployment, the spore can act as an immobilisation matrix as well as a screening scaffold. In this production context, sporulating bacteria are engineered to produce the protein of interest and self-assemble the spore and enzymes into a particle. This production mechanism is distinct from the external CFPS expression used during screening. The intended industrial outcome is a deployable, spore-associated catalyst or sorbent format, without a separate immobilisation redesign between the engineered variant and the final catalyst. ### Stability and durability Caravel describes the following properties and development opportunities: - **Thermostability:** academic studies and Caravel's internal work have documented improved protein thermostability associated with spore display. - **Extreme-pH applications:** spores are stable under pH extremes, and proteins can be engineered toward a desired function under such conditions. Spore stability alone is not a claim that every displayed protein retains activity at those extremes. - **Operational durability:** spores can function as durable beads in scaled reactor systems, supporting low-cost production of heterogeneous catalysts. This reference provides no numerical temperature, pH, lifetime, or performance guarantees. Distinguish reported results from proposed applications and campaign-specific engineering goals. ### Carbon capture and Shell partnership Caravel has an announced carbon-capture partnership with Shell. Caravel used its experimental loop to engineer a carbonic anhydrase with substantially improved thermostability. The source materials do not provide a numerical improvement or detailed operating conditions. Further campaigns under the partnership are described as in progress; their details are not disclosed here. ### Manufacturing and scale-up Bacillus subtilis and other sporulating bacteria are established for use as industrial fermentation and spore production organisms. Caravel's scale-up approach uses existing contract fermentation and spore-extraction capacity rather than requiring investment in an owned spore-production plant. The source materials describe commercially available fermentation capacity ranging from hundreds to tens of thousands of litres, supporting a path to kilogram and ton quantities of spores. This describes the intended scale-up route and available external capacity, not a claim that Caravel already operates its own facility at that scale. ### Commercial scoping Industrial work is priced per campaign for a delivered functional outcome and subsequent royalty revenue. Technical scoping precedes pricing. Enzyme campaigns include development of any necessary fluorogenic assay before high-throughput screening can begin. Carbon capture is the specific industrial application supported by a described partnership and result in this reference. Other applications, including rare-earth separation and industrial proteins, require direct discussion; no specific result or standard offering is established here for them. ## Cost structure and position in the development process Caravel's cost model combines two main mechanisms: - **DNA-synthesis amortisation:** one synthesised sequence supplies a large variant library, reducing synthesis cost per measured variant. - **Small reaction volumes:** picolitre-scale droplets replace conventional 20–40 microlitre plate wells, reducing reagent and CFPS licensing costs per reaction by several orders of magnitude. Caravel positions this cost structure against conventional contract research organisation (CRO) workflows. No specific customer price or guaranteed savings percentage is disclosed here. The intended development sequence is: 1. Computational design by a customer, partner, or Caravel within a delivered campaign. 2. Ultra-high throughput experimental screening by Caravel. 3. Plate-based confirmatory assays for selected candidates. 4. Validation against the customer's targets and application requirements. Caravel delivers experimental screening data and engineered candidates. Screening does not replace confirmatory assays, customer validation, or regulatory-grade characterisation. ## Current scope and constraints - **Soluble proteins are the current standard scope.** Membrane proteins are accepted but may require additional time for validation of function while spore displayed. Membrane or other insoluble protein work requires case-by-case collaboration and should not be presented as a validated standard offering. - **Two weeks is the minimum loop cadence per iteration.** DNA synthesis turnaround is the main constraint. Additional instruments can increase throughput, but do not remove this cadence floor. - **Enzyme campaigns require bespoke fluorogenic readouts.** Assay development and technical scoping are required before screening. - **Post-translational modifications are not automatic.** If the selected CFPS system does not natively provide a required modification, bespoke lysate development may be needed and can be completed by Caravel. - **Scale estimates are approximate.** Variant counts and total data-point targets are order-of-magnitude planning figures, not delivery guarantees. - **Performance is campaign-specific.** Do not infer quantitative efficacy, industrial durability, or validation results that are not provided here. ## Track record, facilities, and collaborators Caravel operates BSL-2 laboratories. The supplied company information identifies: - **Shell:** an announced carbon-capture partnership, including carbonic anhydrase engineering for improved thermostability. - **NSF-funded research:** participation and leadership in a $7.8 million programme, with Caravel directly receiving $2.2 million to lead a three-year project with Avery Bio, Caltech, Rutgers University, and Oregon State University. The $7.8 million programme total is not Caravel's direct award amount. - **Rubi Laboratories:** collaboration involving real-world enzyme testing. - **vHive Animal Health Incubator:** a relationship with the University of Surrey incubator, supported by Zoetis. No additional partnership terms or undisclosed campaign details are provided here. ## Team and advisors Trevor Nicks is Founder & CEO. The source materials list these roles: Founder & CEO, CSO, CTO, CINO, Head of BioInorganic Engineering, Founding Infrastructure Engineer, Biotechnology Engineer I and II, Bioprocess Engineer, Engineering Research Associate, Biotechnologists, and Laboratory Managers. - The CTO has a software-engineering background and experience applying machine learning to biology, and is described as a co-author of a published paper with OpenAI on CFPS optimisation. - The CSO specialises in ultra-high-throughput screening for genome, protein, and enzyme engineering. - The CINO specialises in synthetic biochemistry and rare microbial systems. Public advisors listed in the source materials are Kevin Gray, PhD, for biochemical manufacturing strategy; Eve Hanks, PhD, for animal-health strategy; and Michael Jewett, PhD, for cell-free systems. ## Company stage and enquiries As of November 11, 2026, Caravel is pre-seed and raising capital. The round size is not disclosed. Confirm current fundraising status directly with the company. For commercial scoping, scientific questions, security documentation, partnership discussions, investment enquiries, or information not covered here, contact [Caravel Bio team](mailto:hello@caravel.bio).